SGN-BB228 IS A FIRST-IN-CLASS CD228-TARGETED COSTIMULATORY ANTIBODY ANTICALIN® BISPECIFIC DELIVERING POTENT AND CONDITIONAL 4-1BB COSTIMULATION TO TUMOR-SPECIFIC T CELLS

被引：0
|
作者：
Heiser, Ryan [1 ]
机构：
[1] Seagen Inc, Bothell, WA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.1201
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1201
引用
收藏
页码：A1245 / A1245
页数：1
相关论文
共 14 条
  • [1] SGN-BB228, a CD228-directed costimulatory antibody anticalin® bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T cell exhaustion
    Updegraff, Barrett
    Urban, Johannes
    Mutschler, James
    Szeto, Gregory L.
    O'Connor, Brian P.
    Gardai, Shyra J.
    Heiser, Ryan A.
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).
    Henry, Jason Timothy
    Mehnert, Janice M.
    Rudnicki, Erika
    Pinelli, Juan
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
    Dummer, R.
    Daud, A.
    Eigentler, T. K.
    Evans, T. R. J.
    Henry, J.
    Hodi, F. S.
    Miller, W. H.
    Robert, C.
    Saibil, S.
    Tachiki, L.
    Nayeri, M.
    Xing, B.
    Mehnert, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S709 - S709
  • [4] Claudin 18.2 X 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation
    Jiang, Wenqing
    Fang, Lei
    Wang, Zhengyi
    Guo, Taylor B.
    Park, Eunyoung
    Sung, Eunsil
    Jung, Jaeho
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Preclinical toxicology and pharmacology for the 4-1BB/HER2 bispecific PRS-343: A first-in-class costimulatory T cell engager
    Hinner, Marlon J.
    Aiba, Rachida-Siham Bel
    Jaquin, Thomas
    Berger, Sven
    Durr, Manuela
    Schlosser, Corinna
    Allersdorfer, Andrea
    Rothe, Christine
    Matis, Louis A.
    Olwill, Shane A.
    CANCER RESEARCH, 2017, 77
  • [6] Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
    Hinner, Marlon J.
    Aiba, Rachida Siham Bel
    Jaquin, Thomas J.
    Berger, Sven
    Duerr, Manuela Carola
    Schlosser, Corinna
    Allersdorfer, Andrea
    Wiedenmann, Alexander
    Matschiner, Gabriele
    Schueler, Julia
    Moebius, Ulrich
    Rothe, Christine
    Matis, Louis
    Olwill, Shane Anthony
    CLINICAL CANCER RESEARCH, 2019, 25 (19) : 5878 - 5889
  • [7] A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells
    Shen, Aolin
    Liu, Wenting
    Wang, Huizhen
    Zeng, Xiaoli
    Wang, Mengli
    Zhang, Dayan
    Zhao, Qun
    Fang, Qing
    Wang, Fengrong
    Cheng, Liansheng
    Shen, Guodong
    Li, Yongxiang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (07): : 3246 - 3256
  • [8] HBM7008, A FIRST-IN-CLASS BISPECIFIC ANTIBODY TARGETING BOTH B7-H4 AND 4-1BB, EXHIBITS ROBUST ANTI-TUMOR IMMUNITY AND LOW TOXICITY THROUGH B7-H4-DIRECTED 4-1BB ACTIVATION
    Huang, Bing
    Du, Fangfang
    Lv, Xiaocheng
    Zhao, Jianxun
    Chen, Fei
    Lu, Zailian
    Zhang, Yang
    Chen, Victor
    Gan, Xin
    Zhao, Jiuqiao
    He, Yun
    Wu, Xiaodong
    Rong, Yiping
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1099 - A1099
  • [9] BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and < for vivo antitumor activity and < for superior safety profile in preclinical models
    Li, Zhuo
    Qu, Liang
    Chen, Xin
    Xue, Liu
    Li, Jie
    Liu, Qi
    Sun, Jian
    Sun, Hanzi
    Chen, Yun
    Xie, Yuanyuan
    Wang, Wanyi
    Zhu, Lin
    Wang, Penghao
    Zhou, Xiaosui
    Hou, Hongjia
    Chen, Jie
    Liu, Xinyi
    Zhang, Yilu
    Liu, Ning
    Liang, Xinyi
    Zhang, Shuo
    Tang, Xiaoyan
    Song, Jing
    Zhang, Tong
    Song, Xiaomin
    Liu, Xuesong
    Li, Kang
    Huang, Chichi
    CANCER RESEARCH, 2024, 84 (06)
  • [10] ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT
    Jung, Uijung
    Jeon, Jaehyoung
    Lee, Shinai
    Jin, Hyung-Seung
    Kim, Youngkwang
    Sung, Eunsil
    Kim, Hyunjoo
    Lim, Yangmi
    Won, Jonghwa
    Wang, Zhengyi
    Jiang, Wenqing
    Jung, Jaeho
    You, Gihoon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A935 - A935
12